Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, on November 18, 2025. The report details the filing of a prospectus supplement to expand the company's "at-the-market" (ATM) equity offering program.
Key Financial Metrics and Capital Activities
- ATM Program Capacity: The company filed to offer and sell up to $3,438,062 of additional common stock under its existing ATM Agreement.
- Historical Sales: As of the filing date, the company has sold an aggregate of $9,386,964 of common stock pursuant to the ATM Agreement since its inception.
- Underwriter Compensation: H.C. Wainwright & Co., LLC serves as the sales agent and is entitled to a commission of 3.0% of the gross sales price of shares sold.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these operational financial indicators.
Material Changes and Program Details
The primary material event is the expansion of the company's ability to raise capital through the ATM program. The company retains the discretion to set sale parameters, including share volume, timing, daily limits, and minimum price thresholds. The agreement allows for termination by either party upon written notice, with specific provisions for termination by the agent in the event of a material adverse change.
Outlook, Risks, and Management Commentary
- Management Discretion: The company has no obligation to sell any shares and may suspend the program at any time.
- Legal Validation: Blank Rome LLP has issued a legal opinion regarding the validity of the shares to be offered.
- Risk Factors: The filing notes that sales are subject to market conditions and the company's ability to set minimum price floors. The agreement includes customary indemnification obligations.
Key Facts for Investor Verification
- Verify the current share price and trading volume to assess the potential dilution impact of selling up to $3.4 million in additional shares.
- Review the company's most recent 10-Q or 10-K to determine current cash reserves and burn rate, as this 8-K does not provide liquidity data.
- Confirm the total number of shares outstanding to calculate the percentage increase in share count if the full $3.4 million is sold.
- Monitor future 8-K filings for actual sales executed under this expanded capacity.